X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TCB008 (omnImmune) is an allogeneic unmodified cell therapy consisting of activated and expanded gamma delta T cells. It is under phase 2 clinical trials for treatment of patients suffering from relapse/refractory Acute Myeloid Leukemia (AML).
Lead Product(s): TCB008
Therapeutic Area: Oncology Product Name: TCB008
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
The Company intends to use the net proceeds to support its upcoming clinical trial focusing on relapse/refractory Acute Myeloid Leukemia, evaluating OmnImmune, an allogeneic unmodified cell therapy that consists of activated and expanded gamma delta T-cells.
Lead Product(s): Allogeneic Gamma Delta T-cell Therapy
Therapeutic Area: Oncology Product Name: OmnImmune
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: H.C. Wainwright & Co
Deal Size: $3.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 22, 2023
Details:
The Company intends to use the net proceeds to support its upcoming clinical trial focusing on relapse/refractory Acute Myeloid Leukemia, evaluating OmnImmune, an allogeneic unmodified cell therapy that consists of activated and expanded gamma delta T-cells.
Lead Product(s): Allogeneic Gamma Delta T-cell Therapy
Therapeutic Area: Oncology Product Name: OmnImmune
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: H.C. Wainwright & Co
Deal Size: $3.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 19, 2023
Details:
TCB008 (omnImmune) is an allogeneic unmodified cell therapy consisting of activated and expanded gamma delta T cells. It is under phase 2 clinical trials for treatment of patients suffering from relapse/refractory Acute Myeloid Leukemia (AML).
Lead Product(s): OmnImmune
Therapeutic Area: Oncology Product Name: TCB008
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
OmnImmune® is our unmodified allogeneic gamma delta T cell product which constantly monitor cancerous or infected cells, and are one of the first lines of defense against disease.It is being initially used for the treatment of Acute Myeloid Leukaemia (AML).
Lead Product(s): Allogeneic Gamma Delta T Cell
Therapeutic Area: Oncology Product Name: OmnImmune
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2023
Details:
TCB-008, an allogeneic unmodified cell therapy consisting of activated and expanded gamma delta T cells, which is investigated for the treatment of relapse/refractory Acute Myeloid Leukemia.
Lead Product(s): TCB-008
Therapeutic Area: Oncology Product Name: TCB-008
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2023
Details:
The collaboration aims to research the therapeutic potential of gamma-delta T cells and their role in gut barrier protection against microbial infection and inflammation for the treatment of mucosal infections.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Queen Mary University of London
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 05, 2023
Details:
TCB-008 is an allogeneic gamma-delta T cell therapy which is being investigated as a promising monotherapy for the patients with acute myeloid leukemia.
Lead Product(s): TCB-008
Therapeutic Area: Oncology Product Name: TCB-008
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2023
Details:
OmnImmune® is our unmodified allogeneic gamma delta T cell product which constantly monitor cancerous or infected cells, and are one of the first lines of defense against disease.It is being initially used for the treatment of Acute Myeloid Leukaemia (AML).
Lead Product(s): Allogeneic Gamma Delta T Cell
Therapeutic Area: Oncology Product Name: OmnImmune
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2023
Details:
TC BioPharm is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T-lymphocyte product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia using the Company's proprietary allogenic CryoTC technology.
Lead Product(s): Gamma Delta T-lymphocyte,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: OmnImmune
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 17, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
